Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical To Start Generic Protonix Sales in U.S.

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Sun Pharmaceutical said it would immediately begin sales of a generic version of Wyeth's heartburn drug Protonix (pantoprazole) in the U.S., a move expected to be matched by Israel's Teva Laboratories for a market estimated at $2.3 billion
Advertisement

Related Content

The Year Ahead: Hard Times For Indian Generics May Force Switch To Innovation
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
India’s Sun Pharma To Pursue Taro Merger As Q4 Profits Surge On U.S. Protonix Sales
Nycomed To Outsource API Production To India
Nycomed To Outsource API Production To India
Sun Pharma Buys Additional Stake In Taro, Will Tender Offer Follow?
Sun Pharma Buys Additional Stake In Taro, Will Tender Offer Follow?
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
Sun Pharmaceutical Moves To Buy Taro In $450 Million Deal
Sun Pharmaceutical Moves To Buy Taro In $450 Million Deal
Advertisement
UsernamePublicRestriction

Register

SC066777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel